米氮平联合西酞普兰片治疗抑郁症的疗效观察

Observation on the Efficacy of Mirtazapine Plus Citalopram Tablets in the Treatment of Depression

目的研究米氮平联合草酸艾司西酞普兰片治疗抑郁症的临床疗效。方法本次纳入2017年11月—2018年10月收治的78例抑郁症患者展开研究,按照随机数字表法分为两组,对照组39例采用草酸艾司西酞普兰片治疗,观察组39例采用米氮平联合草酸艾司西酞普兰片治疗。比较两组的临床疗效、抑郁评分、用药安全性。结果观察组抑郁症患者的临床总有效率高于对照组,HAMD-17 评分、MADRS 评分均低于对照组,差异具有统计学意义(P < 0.05);两组的不良反应发生率进行比较,差异具有统计学意义(P < 0.05)。结论对抑郁症患者实施米氮平联合草酸艾司西酞普兰片治疗的效果确切,有助于抑郁症状的改善,用药安全性较高。

Objective To study the clinical efficacy and safety of mirtazapine combined with escitalopram oxalate in the treatment of depression. Methods A total of 78 patients with depression who were admitted from November 2017 to October 2018 were enrolled in the study. They were divided into two groups according to the random number table method, and 39 patients in the control group were treated with escitalopram oxalate tablets. 39 patients were treated with mirtazapine combined with escitalopram oxalate tablets. The clinical efficacy, depression score, and medication safety of the two groups were compared. Results The total clinical effective rate of patients with depression in the observation group was higher than that of the control group. The HAMD-17 score and MADRS score were lower than the control group, and the difference was statistically significant (P < 0.05). The incidence of adverse reactions in the two groups was compared. The difference was statistically significant (P < 0.05). Conclusion The treatment of mirtazapine combined with escitalopram oxalate in patients with depression is effective, which contributes to the improvement of depressive symptoms and the safety of medication.